相关临床试验
25
10 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
8
32.0%
Approved For Marketing
1
4.0%
已完成
9
36.0%
尚未招募
2
8.0%
招募中
1
4.0%
终止
1
4.0%
Unknown
3
12.0%
暂无批准数据
- Vericel Corporation received FDA approval for commercial MACI manufacturing at its new Burlington, Massachusetts facility, marking a significant regulatory milestone for the cell therapy company. - The approval enables commercial production to begin in the second quarter of 2026, substantially increasing manufacturing capacity to meet growing demand for the cartilage repair therapy. - The expanded manufacturing capability positions Vericel to potentially commercialize MACI outside the United States for the first time. - The state-of-the-art facility strengthens Vericel's supply chain for its autologous cultured chondrocyte therapy used to repair knee cartilage defects.
- MediWound announced peer-reviewed clinical data showing NexoBrid® reduced pigmented wound surface by 92.5% in patients with traumatic tattoos from friction and blast injuries. - The prospective study of 15 patients at Sheba Medical Center demonstrated that NexoBrid® removed 96% of visible pigments in abrasive injuries and 84% in explosive injuries. - The enzymatic debridement treatment was well-tolerated with no adverse events, offering a precision alternative to aggressive mechanical scrubbing for embedded particle removal. - This represents the first published series evaluating enzymatic debridement for traumatic tattoo prevention, supporting further evaluation in acute trauma settings.
